Journal article

A Multicenter Phase 2 Study of Risk-adjusted Salvage Chemotherapy Incorporating Vinorelbine and Gemcitabine for Relapsed and Refractory Lymphoma

Sant-Rayn Pasricha, Andrew Grigg, John Catalano, Michael Leahy, Craig Underhill, Chris Arthur, James D'Rozario, Ray Lowenthal, Kate Reed, Andrew Spencer

CANCER | WILEY | Published : 2008


BACKGROUND: Administration of salvage chemotherapy to patients with relapsed or refractory lymphoma is associated with significant toxicity. Vinorelbine and gemcitabine are novel chemotherapeutic agents with minimal overlapping toxicity. We present a phase 2 study of vinorelbine and gemcitabine with or without ifosfamide administered in an ambulatory care setting for relapsed or refractory lymphoma. METHODS: Ninety patients were enrolled. Group 1 comprised patients with "good" risk disease, Group 2 comprised patients with "high" risk disease, and Group 3 comprised patients relapsing after prior stem cell transplant. Patients in Group 1 and Group 3 received vinorelbine and gemcitabine with fi..

View full abstract